SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Verve Therapeutics, Inc. - VERVNewsfile Corp • 01/07/23
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verve Therapeutics, Inc. - VERVPRNewsWire • 01/04/23
Verve Therapeutics Stock Skids On The FDA's Long List Of Gene-Editing ConcernsInvestors Business Daily • 12/05/22
Verve Therapeutics (VERV) Reports Q3 Loss, Lags Revenue EstimatesZacks Investment Research • 11/07/22
Verve Therapeutics Provides Regulatory Update on VERVE-101 Investigational New Drug Application and Reports Third Quarter 2022 Financial ResultsGlobeNewsWire • 11/07/22
Why Shares Of CRISPR-Focused Verve Therapeutics Just Took A Grim TurnInvestors Business Daily • 10/31/22
CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?Investors Business Daily • 10/20/22
Cathie Wood's Ark Invest Adds $23M Of Verve Therapeutics Shares As Stock Drops 10% In A Month - Verve Therapeutics (NASDAQ:VERV)Benzinga • 09/26/22
Verve Therapeutics Announces Clearance of Clinical Trial Authorisation Application by the United Kingdom Medicines and Healthcare Products Regulatory Agency for VERVE-101 in Patients with Heterozygous Familial HypercholesterolemiaGlobeNewsWire • 09/21/22
Verve Therapeutics Highlights Preclinical Data Supporting Nomination of VERVE-201 ANGPTL3 Product Candidate at the European Society of Cardiology 2022 CongressGlobeNewsWire • 08/22/22
Verve Therapeutics Provides Corporate Updates and Reports Second Quarter 2022 Financial ResultsGlobeNewsWire • 08/09/22
Verve Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional SharesGlobeNewsWire • 07/25/22